Chronic Cough

In China, chronic cough is prevalent and associated with poorer health status, especially among adults aged at least 50 years and those with COPD or small airway dysfunction, researchers reported.

The FDA has issued a complete response letter declining to approve a new drug application for gefapixant to treat adults with refractory and unexplained chronic cough, according to a press release issued by Merck.

The Healio Editors compiled the most-read chronic cough news published in 2021.

Chronic cough is common among adults living in Austria and is highly prevalent among older individuals, researchers reported in Respiratory Medicine.

The Healio Editors have compiled a list of the most-read news in pulmonology posted in October.

A pooled analysis of the COUGH-1 and COUGH-2 trials demonstrated long-term efficacy of twice-daily gefapixant out to 52 weeks in patients with refractory or unexplained chronic cough, according to data presented at the CHEST Annual Meeting.

This week, low-dose azithromycin did not improve cough in patients with IPF; tele-pulmonary rehab may lower barriers to care; the J&J vaccine protects against the delta variant; and more.

Treatment with low-dose azithromycin for chronic cough in patients with idiopathic pulmonary fibrosis did not significantly improve cough-related quality of life, severity or frequency compared with placebo.

Lidocaine, delivered as a throat spray to the pharynx, reduced cough frequency in adults with refractory chronic cough, according to data published in the Journal of Allergy and Clinical Immunology: In Practice.

Gefapixant 45 mg twice daily resulted in clinically important reductions in cough frequency compared with placebo in patients with refractory or unexplained chronic cough.